TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline In Craniomandibular Index (CMI) Scores At 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cheerful mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of post-op complications
Endpoint domain: Adverse events/effects
Primary endpoint: Phacodepth Required to Achieve Full Thickness Nuclear Crack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with defervescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Alive at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: change of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breath carbon monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR rates at week 12 after treatment stop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Eyberg Child Behavior Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Connor-Davidson Resilience Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Parent Stress Index - Short Form Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Family Assessment Device score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Perceived efficacy of patient-physician interactions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety Assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete wound closure (epithelialisation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: In-stent Late Lumen Loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Montgomery-Äsberg Depression Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale for pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Optic nerve sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bleeding free probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with ALT reduced to ≤ 60 U/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Maximum Diameter of the Inferior Vena Cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Minimum Diameter of the Inferior Vena Cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Collapse of the Inferior Vena Cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Exam result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception and satisfaction questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of correct responses regarding urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement of symptoms of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time in hypoglycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time in severe hyperglycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Stopped Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinical laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-24) of Plasma Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Plasma Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC (0-24) of Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rmax (0-24) of Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TCD Time-averaged Mean Velocity (TAMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Highly-sensitive C-reactive Protein (hsCRP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Interleukin 6 (IL-6) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chronic postoperative inguinal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intestinal microbial spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of drug- and sex-related HIV risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of frequency of illicit opiate use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B Virus (HBV) DNA Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with VTE event (DVT and/or PE)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Major adverse kidney event
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline cardiorespiratory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PFA-100 quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient satisfaction with ccfDNA testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative bioavailability value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound sensitivity to identify a full stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: T cell metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Carotid Plaque Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of biopsychosocial status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum uric acid control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to Locoid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in dermal blood flow response to capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Achieved Immune Tolerance Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Physical Examination Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Vital Signs Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gastrointestinal Quality of Life Index (GIQLI) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes in cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in blood hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of heart fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spontaneous Bowel Movement Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tolerance of the Test Product on the Scalp
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder Pain Intensity Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean Doses Given
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Child Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matsuda Insulin Sensitivity Index (MISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to patient-reported need for thoracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction angle assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip-knee-ankle angle assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mikulicz point assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior slope assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of tanespimycin with cytarabine
Endpoint domain: Adverse events/effects
Primary endpoint: ctDNA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of study subjects having BCG-related IRIS within 48 weeks of initiating HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of study subjects having unmasking and paradoxical TB-related IRIS within 48 weeks of initiating HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 T-cell count and percentage and plasma viral load, 48 weeks post-HAART initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve (AUC∞) of ULTRAM ER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Increase in Meal-induced Total GLP-1 Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Restoration of the Insulinotropic Effect of GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Central Line Placement Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in methadone dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-free urine test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completing at least one recommended cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of severity adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of specific laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in illicit ATS use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in bone mineral density from baseline to 8 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tibia bone characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arterial compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Insulin-like Growth Factor-1 (IGF-I) and Insulin-like Growth Factor BP3 (IGFBP3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Loss of HbsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Movement of Normal Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation Coefficient for the Association Between Delivered Mean Parotid Dose and Salivary Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum expression of miR-192
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum expression of miR-25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine expression of miR-192
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine expression of miR-25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: DVT Incident Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in health anxiety levels measured by the Whiteley Index 7 (WI7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in health anxiety levels measured by the Bodily Perception Questionnaire (BP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Leg Lean Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Experiencing Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Collection of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in clinical laboratory safety assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in electrocardiogram (ECG) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline for clinical chemistry assessments (ALT, AST, ALP, Total and Direct Bilirubin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-lead ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative thrombosis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients included during a 12-months period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ratio of patient included vs patient admissible according to the screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Deadline for completion of PET MRI
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tolerance of the PET-MRI
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin and C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: operative difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: biliary injury
Endpoint domain: Adverse events/effects
Primary endpoint: Subcortical white matter evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of internal pudendal artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: First Bowel Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum tolerated dose (MTD) of intraperitoneal carboplatin with intravenous paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events in patients given intraperitoneal carboplatin with intravenous paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Number of observed DLTs in patients given intraperitoneal carboplatin with intravenous paclitaxel and intravenous bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic Adequacy Scores for Cytologic Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Adequacy Scores for Histologic Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects at Risk of Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary Function Tests - FEV1/FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Function Tests - FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Function Tests - FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Function Tests - PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Function Tests - MVV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional Capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Complete Responses (CR or CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of true short esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Catheter tip location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability not to deteriorate in functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: accuracy of defibrillator pad detection of breaths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled breath condensate pH change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: digital perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: digital temperature recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Tolerated All Initiated HYQVIA Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion with treatment failures
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerable dose without toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience at Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced at Least One or More Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade >=3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to achieve pulmonary vein isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of improvement in numerical pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of improvement in Neck Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in soluble C5b-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median Tumor Volume Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of Interstitial Lung Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of Idiopathic Pulmonary Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes